Drug Trial Radar · NCT05132075
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
95
Actual
Start
Jun 15, 2022
Primary completion
Sep 3, 2026
Study completion Oct 5, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.
Conditions
- Non-Small Cell Lung Cancer
Interventions
JDQ443Drug
JDQ443 tablets, orally administered
docetaxelDrug
docetaxel concentrated solution for infusion, intravenously administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: Approximately up to 24 months
Locations
51 sites in 25 countries. Site status is shown where the registry gives one.
Valley Medical Center Research
Renton, Washington
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Pilar, Buenos Aires, Argentina
Novartis Investigative Site
Auchenflower, Queensland, Australia
Novartis Investigative Site
South Brisbane, Queensland, Australia
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Sherbrooke, Quebec, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Fuzhou, Fujian, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Harbin, Heilongjiang, China
Novartis Investigative Site
Changsha, Hunan, China
Novartis Investigative Site
Shengyang, Liaoning, China
Novartis Investigative Site
Jinan, Shandong, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Turku, Finland
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Heraklion Crete., Greece
Novartis Investigative Site
Athens, GR, Greece
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Kowloon, Hong Kong
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Reykjavik, Iceland
Novartis Investigative Site
Delhi, India
Novartis Investigative Site
Jaipur, Rajasthan, India
Novartis Investigative Site
Lucca, LU, Italy
Novartis Investigative Site
Aviano, PN, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Amman, Jordan
Novartis Investigative Site
Ed Daoura, Lebanon
Novartis Investigative Site
Kuala Lumpur, Malaysia
Novartis Investigative Site
Kuching, Sarawak, Malaysia
Novartis Investigative Site
Mexico City, Mexico
Novartis Investigative Site
Matosinhos Municipality, Portugal
Novartis Investigative Site
Porto, Portugal
Novartis Investigative Site
Cluj-Napoca, Cluj, Romania
Novartis Investigative Site
Ljubljana, Slovenia, Slovenia
Novartis Investigative Site
Seongnam-si, Gyeonggi-do, South Korea
Novartis Investigative Site
Córdoba, Spain
Novartis Investigative Site
Madrid, Spain
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.